June Off to a Poor ...
Health Care: Drugs
AVANIR Pharmaceuticals (AVNR: NASDAQ)
$2.82 -0.15 | -5.05%
06/01/12 - 04:00 PM ET
Company Cash Flow
| Sep 2011 | Sep 2010 | Sep 2009 | Sep 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -60.63M | -26.69M | -22.00M | -17.50M |
| Operating Gains/Losses | 9.27K | 0.00 | 266.21K | -1.02M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -2.01M | 0.00 | 0.00 | 72.00K |
| (Increase) Decrease in Inventories | -164.34K | -56.21K | 508.65K | 21.71K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 1.29M | 761.37K | 762.27K | 144.15K |
| (Decrease) Increase In Other Current Liabilities | 3.71M | 551.85K | -942.52K | -3.30M |
| (Increase) Decrease In Other Working Capital | -685.42K | -1.44M | -2.57M | 0.00 |
| Other Non-Cash Items | 3.78M | 2.75M | 2.88M | 1.64M |
| Net Cash From Continuing Operations | -56.52M | -23.80M | -20.29M | -18.04M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 1.37M |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -56.52M | -23.80M | -20.29M | -16.68M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 5.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 66.92K | 388.12K | 2.30M |
| Purchases of Property, Plant & Equipment | -1.82M | -213.41K | -33.01K | -134.37K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 210.00K |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | -527.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 2.25K | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -3.47M | -346.49K | 357.36K | 1.03M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 100.19M | 31.64M | 10.25M | 37.84M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | -25.74K | -11.26M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 575.24K | -212.66K | -186.26K | -29.58K |
| Net Cash From Financing Activities | 100.77M | 31.43M | 10.03M | 26.55M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 40.77M | 7.29M | -9.90M | 10.90M |
Portfolios with AVNR
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Most Shorted Stocks in B...
- Contributor5 Stocks Under-$10 Setting ...
- Contributor5 Biotech Drug-Launch Stock...
- ContributorBreakout Stocks Of The Week...
- UserMy Portfolio
- Contributor6 Heavily Shorted Stocks 04...
- Contributor5 Stocks With the Largest S...
- Usergm401
- Userparvardigar
Latest AVNR Headlines from TheStreet
- Avanir Pharmaceuticals CEO Presents At Bank Of America Merrill Lynch Health Care Conference (Transcript) 05.17.12 | 05:05 pm
- Avanir Pharmaceuticals' Presents At Deutsche Bank Securities Annual Health Care Conference (Transcript) 05.09.12 | 11:05 pm
- Avanir Pharmaceuticals' CEO Discusses F2Q2012 Results - Earnings Call Transcript 05.08.12 | 03:05 pm
- Avanir's CEO Presents At Citi 2012 Global Health Care Conference - Transcript 02.29.12 | 01:02 pm
- AVANIR Pharmaceuticals' CEO Discusses F1Q12 Results - Earnings Call Transcript 02.07.12 | 10:02 pm
- Friday's Top 10 Articles, Videos on TheStreet 01.20.12 | 02:01 pm
- Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger 01.20.12 | 05:01 am
- AVANIR Stock Hits New 52-Week Low (AVNR) 12.14.11 | 03:12 pm
- Avanir's CEO Discusses Q4 2011 Results - Earnings Call Transcript 12.12.11 | 11:12 pm
- Biotech Stock Mailbag: 2011 Report Card 11.25.11 | 05:11 am
Press Releases for AVNR
- Avanir Pharmaceuticals To Present At Jefferies 2012 Global Healthcare Conference - PR Newswire 05.29.12 | 08:05 am
- Avanir Pharmaceuticals To Present Data At The American Academy Of Neurology Annual Meeting - PR Newswire 04.17.12 | 08:04 am
- Avanir Pharmaceuticals To Present At BioCentury Future Leaders In The Biotech Industry Conference - PR Newswire 04.10.12 | 08:04 am
- Avanir Pharmaceuticals Announces Appointment Of Rohan Palekar As Chief Commercial Officer - PR Newswire 03.16.12 | 08:03 am
- Avanir Pharmaceuticals To Participate In Two Conferences In March - PR Newswire 03.01.12 | 04:03 pm
- Avanir Pharmaceuticals To Participate In Citi 2012 Global Health Care Conference - PR Newswire 02.21.12 | 09:02 am
- Avanir Pharmaceuticals Announces Publication Of Phase III Study Results Showing Efficacy And Safety Of AVP-923 In The Treatment Of Diabetic Neuropathic Pain - PR Newswire 02.08.12 | 09:02 am
- Avanir Pharmaceuticals Announces Date Of Fiscal 2012 First Quarter Financial Results And Conference Call - PR Newswire 01.30.12 | 08:01 am
- Avanir Pharmaceuticals Announces Date Of Fiscal 2011 Fourth Quarter And Year End Financial Results And Conference Call - PR Newswire 12.06.11 | 08:12 am
- Avanir Pharmaceuticals To Participate In Piper Jaffray Health Care Conference - PR Newswire 11.22.11 | 08:11 am
Partner Headlines for AVNR
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
- Avanir Pharmaceuticals: Limelight On The Horizon - Seeking Alpha 02.17.12 | 06:02 am
- Canaccord Reiterates Buy, $6 PT on Avanir Pharmaceuticals - Benzinga 11.30.11 | 09:11 am
- Avanir - Closing Short Position - Seeking Alpha 11.27.11 | 08:11 am
- 10 Small-Cap Stocks Deeply Undervalued By Target Price - Seeking Alpha 11.11.11 | 10:11 pm
- Avanir Pain Drug Should Provide Long-Term Growth - Seeking Alpha 09.30.11 | 06:09 pm
- Avanir: Congressional Inquiry Into the Pricing of Nuedexta Abandoned - Seeking Alpha 07.22.11 | 09:07 am
- Hearing Negative Chatter in Avanir Pharmaceuticals - Benzinga 06.30.11 | 01:06 pm
- Jefferies' Upadates - Benzinga 06.03.11 | 09:06 am
- Investors Should Take Notice of Congressional Questions Regarding Nuedexta Pricing - Seeking Alpha 05.27.11 | 09:05 am
